In vitro and in vivo exposure of human immunodeficiency the zidovudine resistance -suppressing effect could help to explain the in vivo synergistic result of this combination, we virus type 1 (HIV-1) to the reverse transcriptase (RT) inhibitor lamivudine (3TC) results in the selection of viruses with a studied the effect of addition of zidovudine on 4 patients continuously treated with 3TC and harboring a virus population en-500-to 1000-fold reduced susceptibility [1 -6] . This reduced susceptibility is caused by mutations at codon 184 of the RT coding the 184V. gene: The wild type methionine residue is replaced by either an isoleucine (M184I) or a valine residue (M184V) [1 -6] .
Materials and Methods Codon 184 is located within the active site of RT (YMDD motif) [7 -9] . Changes at this codon affect the enzymatic propStudy population. The original study population consisted of erties of the enzyme [10 -12] . An increased fidelity was de-40 HIV-1-infected patients treated with 3TC [16] . Zidovudine was added to 3TC therapy when patients had been treated with scribed for the 184V-containing RT [13] . It has been speculated 3TC for at least 24 weeks, had a CD4 cell count decline of at least that changes in fidelity may influence the evolution of the press zidovudine resistance in vitro [3, 4] . In vivo, combination Four patients were selected for further studies (C0001, C0011, therapy with 3TC and zidovudine results in a strong and sus-C0020, and C0034). These patients, randomly selected from a tained antiviral response [14, 15] (van Leeuwen R, unpublished subset of patients who were antiretroviral therapy-naive before data). To determine to what extent the increased fidelity and receiving 3TC monotherapy, were subsequently treated with a combination of 3TC and zidovudine. The 3TC monotherapy period consisted of 0.5 mg/kg/day for 78 weeks for patient C0001, 1 mg/ kg/day for 71 weeks for patient C0011, 2 mg/kg/day for 84 weeks Received 30 July 1996; revised 10 February 1997. for patient C0020, and 12 mg/kg/day for 46 weeks for patient C0011, and C0020 were treated with 200 mg/day 3TC and 600
Written informed consent was obtained from all subjects for their participamg/day zidovudine for 101, 101, and 81 weeks, respectively. Pation in the formal 3TC protocols that they subsequently enrolled in, and all of tient C0034 received 600 mg/day 3TC and 600 mg/day zidovudine the major amendments to these protocols. during 2 years of 3TC and zidovudine combination therapy. Hepaof the integrase gene. To introduce an XbaI restriction site at the 3end of the RT gene and to restore the N-terminal part of the rinized plasma was stored at 070ЊC, and PBMC were stored in liquid nitrogen.
integrase gene, a PCR reaction using oligonucleotides 5endRT-SmaNotXba (5-ATCCCCGGGGCGGCCGCTCTAGATGGA-CD4 cell count. CD4 cell counts in peripheral blood were determined by flow fluorocytometry, as previously described [17] .
ATA-3; bp 4214-4244), and 3polM (5-CTTGGATCCACT-ACGATGTCACTATTATCTTG-3; bp 5016-4982) (Pharmacia Viral RNA analysis. RNA was extracted from 100 mL of heparinized plasma according to the method described by Boom et al.
Biotech) was performed. Subsequent cloning of the PCR fragment into HXB2᭡2-261RT (both digested with SmaI and BalI) resulted [18] . Subsequently, the isolated RNA was quantified by use of the prototype Roche assay [19] , and the N-terminal part of the RT gene in the RT-deleted HXB2 molecular clone (lacking aa 2-561) with an intact integrase gene (confirmed by sequence analysis). (nucleotides 2453-3461) was reverse-transcribed and amplified by use of a one-tube RT-polymerase chain reaction (PCR) procedure
Analysis of the biologic sensitivity to 3TC and zidovudine. For the analysis of the biologic sensitivity, patient-derived RT se- [20] .
Proviral DNA analysis. DNA was extracted from 2 1 10 6 patient quences were introduced into an RT deletion clone via homologous recombination [22] . Therefore, amplified proviral DNA (bp 2453-PBMC according to the method described by Boom et al. [18] . Subsequently, the RT gene was amplified using 5% of the purified 4311) was cotransfected with linearized HXB2᭡2-561RT, and amplified proviral DNA or viral RNA (bp 2453-3461) was co-DNA sample, 10 pmol of the oligonucleotide RT18 ( significant decline in HIV-1 RNA concentration (0.9 -3.0 log). tional increase was observed. In most patients, the responses in HIV-1 RNA load were mirrored by the changes in CD4 cell However, ultimately in patients C0001, C0020, and C0034, the HIV-1 RNA concentrations returned to their baseline level after counts (figure 2). Drug susceptibility testing and genotypic characterization Ç1 year. The HIV-1 RNA concentration in patient C0011 increased to the baseline level at week 27. After reaching baseof HIV-1 RT at return to baseline. The susceptibility of HIV-1 RT to zidovudine and 3TC was studied in relation to the line values, HIV-1 RNA levels remained stable in patients C0001, C0020, and C0034, whereas in patient C0011 an addivirus load response ( figure 2) . The plasma population of all patients remained resistant to 3TC (IC 50 , ú100 mM). The virus Relationship of phenotypic and genotypic changes. To directly relate the effect of observed amino acid changes on populations at start of combination therapy were susceptible to zidovudine (IC 50 , 0.006 -0.016 mM). Drug susceptibility deterzidovudine and 3TC susceptibility, RT clones obtained longitudinally from patient C0011 were analyzed ( figure 1; table 3 ). minations and sequencing of at least 4 clones per patient were performed after their RNA concentration had returned to the In the presence of wild type codon 184, the combination M41L / T215Y has been demonstrated to confer a 50-to 60-fold baseline level ( figure 1; table 1 ). Clearly, in 3 of 4 patients, zidovudine IC 50 values had only increased õ20-fold, and in increase in IC 50 (table 3 ). In the background of the 184V, however, M41L / T215Y conferred only a small increase (5-all 4 patients, at least three zidovudine resistance -conferring mutations (M41L / D67N / T215Y/F) were present. The to 14-fold) in IC 50 , and even for this small increase, additional substitutions were required: L210W (clone 1.1) or I135L / M41L, D67N, and T215Y/F amino acid changes were selected in all patients, though not in all clones. The K70R amino acid D192G (clone 1.2) for a 5-fold increase and I135M / M245T (clone 1.3) for a 14-fold increase. change was selected in 3 of 4 patients and a K219E substitution in 1 patient. Two additional substitutions (I135M/L/T and After 2 years of combination therapy, substitutions at codons 41, 210, 215, and 245 were conserved. Additional selection of L210W) were observed in 2 of the 4 patients. In 1 of these 2 patients, an I135V amino acid change was observed at start of amino acid changes at codons 40, 43, and 219 (clone 2.1) or at codons 40, 43, 71, 114, and 253 (clone 2.2) resulted in combination therapy.
To investigate the potential role of the C-terminal part of viruses with a 38-or 68-fold increase in zidovudine resistance, respectively. Clone 2.3 was identical to clone 2.1 but harbored RT, we performed a control experiment in which we analyzed the HIV-1 proviral DNA population after 2 years of combinaa wild type codon 184 and, as a result, was susceptible to 3TC (IC 50 , 1.3 mM) and ú114-fold resistant to zidovudine. tion therapy. Recombinant viruses were made, introducing either the full RT gene (aa 2 -561) or the N-terminal part (aa 2 -261), both derived from the proviral DNA population. The Discussion additional effect of the C-terminal part of RT on zidovudine resistance was limited to õ2-fold in all 4 patients, indicating
This study gives an explanation for the sustained antiviral that changes in the C-terminal part of RT may not play a major effects of 3TC and zidovudine combination therapy. Resistance role in vivo (table 2) . to 3TC is caused by amino acid changes at codon 184 of the HIV-1 RT gene [1 -6] . The 184V substitution has been shown to increase the fidelity of RT [13] and, when introduced into Table 2 . Zidovudine susceptibility of N-terminal part of reverse the background of a zidovudine-resistant RT gene, to suppress transcriptase (RT) and complete RT, obtained from proviral DNA the effect of some zidovudine resistance mutations [3, 4] . We population after 2 years of 3TC and zidovudine combination therapy.
studied the effect of addition of zidovudine in 4 patients contin- 
NOTE. ND, not done. * Data obtained from Tisdale et al. [3] .
HIV-1 RNA concentration to return to the baseline level. At vudine resistance in 3TC-resistant patients suggests an alternative mechanism to explain the prolonged suppression of the that time, in 3 patients the increase in zidovudine IC 50 of the virus population in plasma was only 9-to 20-fold and in the HIV-1 RNA levels during combination therapy. Even in a highly zidovudine-resistant background, the M184V substituother patient was 140-fold. These data are in agreement with an earlier study in which we used the return-to-baseline criterion to tion persisted and continued to have an effect on the level of zidovudine resistance, as illustrated by the difference between define in vivo significant drug resistance [24] . In this previous study in 24 patients receiving zidovudine monotherapy, it was a 184 wild type clone with an IC 50 value ú5 mM and an identical clone harboring the 184V with an IC 50 of 1.5 mM. shown that an 8-to 10-fold increase in zidovudine IC 50 conferred by only one amino acid change (K70R) was sufficient
In the case of the nonnucleoside RT inhibitors, the primary change seen during monotherapy is located at codon 181 to return the virus load to the baseline level. A striking difference was observed when we analyzed the sequences of the RT (Y181C). Similarly to the 184V, this amino acid change suppresses the effect of zidovudine mutations [32] . However, this genes from the patient population receiving 3TC and zidovudine. In patients harboring the 184V, at least three amino acid effect is lost during zidovudine and nevirapine combination therapy, since alternative nonnucleoside resistance changes are changes were required for return to baseline, one of them (T215Y/F) consisting of two nucleotide changes (table 1). The selected that do not suppress zidovudine resistance [33] . The persistence of the 184V during zidovudine and 3TC combinaselected amino acid changes were in most cases identical to those observed during zidovudine monotherapy (codons 41, 67, tion therapy indicates that, unlike the situation with nonnucleoside RT inhibitors, there are no alternatives for the RT enzyme 70, 215, and 219), and some additional amino acid substitutions (codons 135 and 210) previously associated with zidovudine to confer 3TC resistance, pointing at a very specific interaction between RT and this nucleoside analogue. Remarkably, in addiresistance were observed [25 -30] . Of interest, after prolonged combination therapy, additional amino acid changes contributtion to the 184 substitution, no amino acid changes were observed in or around the catalytic site. ing to zidovudine resistance were observed in the areas between aa 40 -44, 64 -74, and 208 -219 (neighboring the classical subIn vitro selection experiments have shown that double-resistance to 3TC and zidovudine could be located in the C-terminal stitutions involved in zidovudine resistance), some of which were previously reported [27, 28, 31] .
part (between aa 333 and 558) of the RT enzyme [34, 35] . In our patients, we could not find evidence for a role of this region Larder et al.
[15] observed a sustained antiviral effect of 3TC and zidovudine compared with zidovudine monotherapy in causing 3TC and zidovudine co-resistance (table 2) . Selection of virus variants with multiple mutations could and theorized that this might be due to the delayed appearance of zidovudine resistance mutations. The observation that multitheoretically be delayed because of increased fidelity of the HIV-1 RT enzyme containing the M184V amino acid change ple amino acid changes are needed to confer significant zido-/ 9D2F$$AU11 
